List of Excipients in Branded Drug DICYCLOMINE HYDROCHLORIDE

Generic Drugs Containing DICYCLOMINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0054-0622	CITRIC ACID MONOHYDRATE
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0054-0622	FD&C RED NO. 40
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0054-0622	GLYCERIN
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0054-0622	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0054-0622	PROPYLENE GLYCOL
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0054-0622	PROPYLPARABEN
Hikma Pharmaceuticals USA Inc	dicyclomine hydrochloride	0054-0622	SORBITOL

What are the Most Frequently-Used Excipients in DICYCLOMINE HYDROCHLORIDE?

# Of NDCs	Excipient
23	ACACIA
1	AKA3
20	ALCOHOL
30	ALUMINUM OXIDE
21	AMMONIA
1	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
64	ANHYDROUS LACTOSE

Dicyclomine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Dicyclomine hydrochloride is a mature, low-cost anticholinergic used primarily for symptomatic treatment of functional bowel and irritable bowel syndrome. Its core oral-solid market is commoditized, with limited patent protection and modest differentiation potential. The strongest commercial opportunities are formulation-led: palatable oral liquids, lower-burden excipient systems, unit-dose products, and reliable supply of low-cost generic capsules and tablets.

The main development constraint is safety rather than formulation complexity. Dicyclomine can cause anticholinergic adverse effects, and the FDA label restricts use in infants younger than six months and in breastfeeding women because of reported serious events and possible infant exposure concerns.[1]

What formulations of dicyclomine hydrochloride are commercially available?

Dicyclomine hydrochloride is marketed in immediate-release oral and injectable dosage forms.

Dosage form	Common strength	Primary commercial role	Excipient opportunity
Capsule	10 mg, 20 mg	Retail generic and branded maintenance therapy	Cost reduction, capsule color and imprint, low-allergen positioning
Tablet	20 mg	Alternative immediate-release oral solid	Direct compression, improved swallowability, low-weight tablet
Oral solution	Commonly 10 mg/5 mL	Patients with dysphagia or difficulty swallowing	Taste masking, preservative system, sugar-free and alcohol-free positioning
Injection	20 mg/2 mL, commonly 10 mg/mL	Short-term intramuscular use	Sterility, preservative strategy, container closure, supply reliability

The reference product is Bentyl, historically associated with Winthrop Pharmaceuticals and later marketed through various commercial arrangements. FDA labeling identifies dicyclomine hydrochloride as the active ingredient and covers oral capsules, tablets, oral solution and intramuscular injection presentations.[1]

The oral products are immediate-release products. There is no major commercial need for a complex modified-release system because the approved product is used for symptomatic relief and the active ingredient has long been available in conventional dosage forms.

What excipients are used in dicyclomine hydrochloride products?

Excipients differ by manufacturer, dosage form, strength and market. The relevant commercial strategy is therefore not to copy a single historical formulation, but to build a robust excipient platform that meets the FDA inactive-ingredient database, manufacturing and patient-use requirements.

Oral capsules

Typical generic capsule systems may use:

• Lactose or another diluent
• Pregelatinized starch or other disintegrant
• Talc or colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Gelatin or hypromellose capsule shells
• Approved colorants and printing inks

A lactose-based capsule is generally inexpensive and familiar to manufacturers. It may be unsuitable for a lactose-free positioning, however, and can complicate marketing claims directed at patients who avoid dairy-derived excipients.

A starch-based, lactose-free capsule platform provides a clearer differentiation point. Hypromellose capsules can support vegetarian and gelatin-free positioning, although the commercial value depends on the target channel and country.

Immediate-release tablets

Tablet formulations may combine a diluent, binder, disintegrant, glidant and lubricant. Suitable candidates include microcrystalline cellulose, dibasic calcium phosphate, mannitol, starch glycolate, crospovidone, povidone, colloidal silicon dioxide and magnesium stearate.

Dicyclomine hydrochloride tablets do not require an extended-release matrix. Development should focus on:

• Low tablet weight
• Rapid disintegration
• Adequate content uniformity at the lower strength
• Mechanical strength during packaging and shipping
• Minimal sticking and picking during compression
• Acceptable swallowing characteristics

A direct-compression formulation can reduce processing steps and manufacturing cost. A wet-granulated formulation may be preferable where the selected active pharmaceutical ingredient has poor flow or poor content uniformity at the 10 mg strength.

Oral solution

The oral solution has the strongest excipient-led differentiation potential. Candidate excipient classes include:

• Purified water as the vehicle
• pH adjusters and buffers
• Sweeteners such as sucralose, sorbitol or other polyols
• Flavor systems
• Preservatives such as parabens or benzoate-based systems, where justified
• Chelating agents where needed for stability
• Viscosity modifiers

The principal development issue is taste. Dicyclomine hydrochloride is a pharmacologically active salt with a pronounced medicinal and potentially bitter taste. A commercial oral solution should use a taste-masking system that remains stable across the labeled shelf life and does not create dosing errors.

Three positioning options are commercially credible:

1. A conventional sweetened and flavored solution with low cost.
2. A sugar-free solution using a polyol or high-intensity sweetener system.
3. A preservative-free or low-preservative presentation supported by a suitable container and microbial-control strategy.

The third option can command a higher price in institutional or specialty channels, but it has a greater development and packaging burden. A unit-dose cup or oral syringe may reduce measurement errors and improve pharmacy dispensing.

How should an excipient strategy address dicyclomine hydrochloride stability?

The formulation target is a chemically and physically stable immediate-release product that does not introduce unnecessary excipient risk.

pH and aqueous stability

The oral solution requires controlled pH because pH affects solubility, taste, preservative performance and packaging compatibility. Development should evaluate a practical pH range rather than optimize for maximum solubility alone. A very acidic or alkaline product may worsen taste, irritate the gastrointestinal tract or reduce preservative performance.

The stability program should examine:

• Assay and degradation products
• Appearance and color
• pH drift
• Precipitation
• Preservative content
• Microbial limits
• Container interaction
• Extractables and leachables
• Dose delivery through the proposed measuring device

The FDA Inactive Ingredient Database is the primary screening tool for selecting excipients and route-specific precedent. It does not replace full product-specific stability, safety or compatibility work.[2]

Solid-state and manufacturing performance

For capsules and tablets, the principal risk is usually manufacturing robustness rather than complicated solid-state control. Development should assess:

• Particle-size distribution of the active ingredient
• Blend uniformity
• Segregation risk
• Lubrication sensitivity
• Dissolution after scale-up
• Water activity and moisture uptake
• Compatibility with gelatin or hypromellose shells

Excessive magnesium stearate or prolonged lubrication can reduce wetting and slow dissolution. The risk is manageable but should be controlled through a defined process window.

Packaging

Packaging is an underused differentiation tool for a mature product. Suitable options include:

• Blister packs for adherence and portability
• High-density polyethylene bottles for low-cost retail supply
• Amber bottles for light protection where needed
• Unit-dose oral solution cups
• Oral syringes for measured liquid dosing
• Tamper-evident closures for pharmacy and institutional channels

A liquid product with an oral syringe can create more value than a minor tablet reformulation because it addresses administration and dosing needs directly.

What excipient restrictions affect dicyclomine hydrochloride commercialization?

The active ingredient’s anticholinergic profile limits some patient segments regardless of excipient selection. Formulation claims cannot eliminate the core pharmacological warnings.

Important restrictions include:

• Contraindication in infants younger than six months
• Contraindication during breastfeeding under the U.S. label
• Caution in patients vulnerable to anticholinergic effects
• Risk of reduced sweating and heat-related complications
• Potential effects on vision, urinary retention and gastrointestinal motility

An oral liquid may improve administration for adults with dysphagia, but it does not automatically create a pediatric indication. A pediatric commercial strategy would require appropriate clinical, labeling and safety support. The FDA label states that safety and effectiveness in pediatric patients have not been established and identifies a specific contraindication for infants below six months.[1]

Excipients also create avoidable regulatory and market-access issues. Developers should evaluate:

• Sugar content for diabetic-patient positioning
• Sorbitol or other polyols for gastrointestinal tolerance
• Ethanol content, if used in a flavor or solvent system
• Sodium load
• Artificial colors
• Preservative sensitivity
• Gelatin source
• Allergen and religious-certification requirements

A "clean-label" formulation can support pharmacy and health-system procurement, but each excipient change must remain compatible with the approved route, dosage form and regulatory filing.

What FDA regulatory pathway applies to generic dicyclomine hydrochloride?

A conventional U.S. generic would normally use an abbreviated new drug application. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference-listed drug, or meet the applicable requirements for a product-specific waiver where permitted.[3]

Orange Book status

Dicyclomine hydrochloride is a legacy small-molecule product. Its principal U.S. commercial barrier is not current innovative patent protection. The relevant review points are:

• Reference-listed-drug identification
• Active ingredient and strength
• Dosage form
• Route of administration
• Therapeutic equivalence rating
• Listed patents, if any
• Exclusivity status
• Discontinued-product status

The FDA Orange Book remains the controlling source for current patent and exclusivity information for listed drug products.[4] A commercial diligence review should examine the current entry for each dosage form rather than assume that all dicyclomine presentations have the same regulatory history.

Paragraph IV challenges

A Paragraph IV challenge is unlikely to be the central market issue for an old, conventional dicyclomine product unless a current listed patent covers a specific formulation, method of use or delivery system. The principal risk for a new entrant is more likely to be:

• ANDA approval timing
• Product-specific bioequivalence requirements
• Manufacturing inspection
• Drug-shortage competition
• Contract manufacturing reliability
• State substitution and payer access

A differentiated formulation may require a 505(b)(2) application rather than an ANDA if it cannot meet the conditions for generic substitution. That route may support a new dosage form or delivery technology, but it carries higher clinical and regulatory costs.

What patents protect dicyclomine hydrochloride products?

The core dicyclomine hydrochloride molecule is mature and is not expected to have a meaningful active-composition patent barrier in the United States. Commercial protection is more likely to arise from:

• Product-specific formulation patents
• Taste-masking technology
• Unit-dose delivery devices
• Container-closure systems
• Combination products
• Manufacturing processes
• Method-of-use claims

These categories offer limited value unless they create a regulatory advantage, materially improve adherence or support a premium price. A formulation patent that covers only a conventional mixture of well-known excipients may face significant validity and obviousness risk.

How strong is the patent estate for dicyclomine hydrochloride?

The patent estate is weak for the base immediate-release capsule and tablet market. A stronger position would require a product with a clear technical effect, such as:

• Measurably improved palatability
• Reduced dosing error
• Extended stability in a liquid vehicle
• Preservative-free multidose performance
• Improved dissolution or content uniformity
• A device that materially improves administration

Trade-secret protection may be more practical than patent protection for optimized flavor systems, process parameters and supplier specifications. Trade secrets do not prevent independent development, but they can protect manufacturing know-how without requiring public disclosure.

What commercial opportunities exist for dicyclomine hydrochloride?

Low-cost generic oral solids

The largest opportunity is efficient supply of capsules and tablets. Buyers typically value:

• Consistent availability
• Competitive acquisition cost
• Multiple bottle sizes
• Reliable wholesaler service levels
• Simple excipient profiles
• Therapeutic-equivalence status

Margins are likely to be limited because the product is mature and multiple manufacturers can compete. The strongest business case is an efficient, vertically controlled product with low manufacturing complexity.

Differentiated oral solution

A better-tasting oral solution can target adults with swallowing difficulty, post-procedure patients and pharmacy settings requiring liquid dispensing. The opportunity is stronger when the product provides measurable advantages:

• Oral-syringe compatibility
• Sugar-free formulation
• Alcohol-free formulation
• Lower preservative burden
• Stable room-temperature storage
• Accurate low-volume dosing
• Reduced sedimentation or precipitation

A solution should not be marketed as pediatric merely because it is liquid. The approved safety profile remains controlling.

Institutional and shortage-response supply

Hospitals, long-term-care facilities and specialty pharmacies may value dependable supply more than minor formulation innovation. Injectable dicyclomine presents a smaller but potentially less crowded opportunity. The main barriers are sterile manufacturing, container-closure qualification and quality-system requirements.

The injectable product is administered intramuscularly under the U.S. label. Intravenous administration is not an appropriate differentiation pathway without a new regulatory basis.[1]

International markets

Outside the United States, dicyclomine may be sold under different brand names, prescription classifications and dosage forms. Opportunities may exist in markets where:

• IBS treatment is underpenetrated
• Oral liquids have limited competition
• Local manufacturers lack reliable supply
• Pharmacy channels favor branded generics
• Unit-dose packaging is valued

Geographic expansion requires separate review of local excipient restrictions, permitted preservatives, labeling requirements, trademark availability and reference-product standards.

How does dicyclomine compare with competing antispasmodics?

Dicyclomine competes with other antispasmodics and symptom-directed gastrointestinal products rather than with a single direct substitute.

Product class	Commercial distinction	Excipient-led opportunity
Dicyclomine hydrochloride	Established anticholinergic antispasmodic	Low-cost solids, palatable liquid, unit dose
Hyoscyamine	Anticholinergic antispasmodic with multiple dosage forms	Sublingual and orally disintegrating formats
Enteric-coated peppermint oil	Non-anticholinergic IBS symptom approach	Enteric coating and odor control
Simethicone combinations	Gas and bloating positioning	Combination-product regulatory and labeling strategy
Mebeverine, where marketed	Market-dependent smooth-muscle antispasmodic	Modified-release and capsule platforms

Dicyclomine’s advantage is established recognition and inexpensive manufacture. Its disadvantage is the anticholinergic adverse-effect burden, which limits premium positioning against non-anticholinergic alternatives.

What generic entry risks exist for dicyclomine hydrochloride?

Generic entry risk is high for conventional capsules and tablets because:

• The active ingredient is old and widely known.
• Immediate-release dosage forms are technically straightforward.
• Patent-based barriers are limited.
• Substitution can move volume quickly to the lowest-cost supplier.
• Formulation changes are easy for competitors to replicate unless protected by meaningful process or device IP.

A differentiated liquid can reduce direct price comparison, but it remains exposed to competing ANDAs or 505(b)(2) products. Manufacturing reliability may be the most defensible commercial advantage.

Key Takeaways

• Dicyclomine hydrochloride is a mature, low-barrier generic opportunity.
• Immediate-release capsules and tablets are primarily cost and supply-chain businesses.
• Oral solution is the strongest excipient-led opportunity.
• Taste masking, sugar-free positioning, oral-syringe dosing and preservative optimization can support differentiation.
• A liquid dosage form does not create a pediatric indication; FDA pediatric restrictions remain important.
• The base molecule has little practical patent protection, so formulation patents must show a clear technical benefit.
• Injectable supply may offer a narrower but more operationally demanding opportunity.
• FDA Orange Book, DailyMed and Inactive Ingredient Database review should anchor product selection and regulatory strategy.[1,2,4]

FAQs

Can dicyclomine hydrochloride be formulated as an orally disintegrating tablet?

Yes, but the commercial benefit is uncertain. An orally disintegrating tablet would need acceptable taste, rapid disintegration and sufficient stability. Because dicyclomine is associated with medicinal taste, taste masking may be the primary technical challenge.

Is a preservative-free dicyclomine oral solution commercially attractive?

It can be attractive where pharmacies and institutions value reduced preservative exposure. The product would require a suitable microbial-control strategy, packaging configuration and stability package. Single-dose packaging may be more practical than a preservative-free multidose bottle.

Can dicyclomine hydrochloride be combined with simethicone?

A combination product may address cramping and gas symptoms, but it would require a separate regulatory and clinical justification. The combination could also create formulation, labeling and patent questions that do not apply to a simple dicyclomine generic.

What is the most defensible intellectual property for a dicyclomine liquid?

The strongest candidates are claims tied to a demonstrated technical effect, such as long-term taste stability, preservative-free multidose performance, controlled dosing or a device-specific delivery system. Conventional sweetener and flavor mixtures are less likely to provide durable protection.

Is dicyclomine hydrochloride suitable for an over-the-counter switch?

The anticholinergic safety profile makes an OTC switch difficult. Any switch would require FDA evaluation of consumer self-selection, labeling comprehension, misuse risk and safe use across the proposed population. A liquid or new excipient system would not by itself resolve those issues.

References

1. U.S. Food and Drug Administration. (n.d.). Bentyl (dicyclomine hydrochloride) prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Content and format. 21 C.F.R. § 314.94.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book